Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sorbitol dehydrogenase (SORD) is a cytosolic enzyme that catalyzes the reversible oxidation of sorbitol to fructose using NAD+ as a cofactor. It plays a key role in carbohydrate metabolism, particularly in the polyol pathway. SORD is expressed ubiquitously, with highest concentrations in the liver and seminal vesicles. Clinically, it serves as a diagnostic marker for liver injury. In tissues with low expression, sorbitol accumulation can lead to diabetic complications. SORD is a therapeutic target for ischemia/reperfusion-induced liver injury and diabetic complications.
Sorbitol dehydrogenase inhibitors modulate glycolytic fluxes and apoptotic pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sorbitol Dehydrogenase (SORD).